The EUREMAP project aims to optimise the marine bioprospecting workflow within the European research community, enabling state-of-the-art research and enhanced capacity for academia and industry. This will be achieved by building upon the existing expertise available within the consortium members (EU OPENSCREEN, EMBL, EMBRC, ELIXIR) to synergise capacities and resources to enhance marine bioprospecting for natural products.

The EUREMAP platform to be developed will consist of a new multidisciplinary marine bioprospecting workflow that integrates the existing technical capacities, thereby increasing the competitiveness of marine natural products in drug discovery and strengthening the blue bioeconomy in line with the European blue growth strategy. The functioning EUREMAP marine bioprospecting workflow will support the discovery of novel bioactive natural products from marine organisms by utilising novel technology to improve the capacity of European Research infrastructures (RIs). The multidisciplinary nature of the marine bioprospecting research space necessarily requires integrating data flows between disparate research fields. As such, while data management components within disciplines may be in place, they may not be adequately formulated to provide the basis for a cohesive and integrated data workflow.

The following dataset descriptions are specific to the EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease.

The project focuses on identifying and characterizing additional streptocyclinones present in the cultures of the marine Streptomyces sp. CA-237351. Known members of the streptocyclinone family have anti-inflammatory and neuroprotective properties). We aim to deepen the understanding of their biosynthesis and potential therapeutic applications and expand the known diversity of streptocyclinone variants.